Table 1.
Comparison of demographic biochemical and clinical data of study population at baseline
| At baseline | n (%) | TC, mean (SE) (mg/dL) | Pa | HDL, mean (SE) (mg/dL) | Pa | LDLa, mean (SE) (mg/dL) | Pa | TC/HDL ratio, mean (SE) | Pa | Medium–high Framingham risk score frequency (%) | Pb |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | |||||||||||
| Female | 135 (76.7) | 182.6 (4.0) | 0.5008 | 49.4 (3.3) | 0.7072 | 97.9 (6.3) | 0.4799 | 4.0 (0.1) | 0.9961 | 2 (1.18) | 0.060 |
| Male | 35 (23.3) | 176.7 (7.4) | 48.3 (1.2) | 107.9 (13.0) | 4.0 (0.3) | 3 (1.76) | (Fisher’s) | ||||
| Age (years) | |||||||||||
| <30 | 26 (15.3) | 161.5 (6.4) | 0.040c | 46.9 (9.2) | 0.062 | 89.0 (17.5) | 0.013c | 3.6 (0.21) | 0.034c | 0 | >0.0001 |
| 30–40 | 54 (31.8) | 174.5 (6.7) | 47.5 (6.5) | 101.9 (13.9) | 3.9 (0.16) | 0 | (Fisher’s) | ||||
| 40–50 | 58 (34.1) | 182.8 (5.2) | 48.0 (6.3) | 102.3 (13.4) | 4.0 (0.16) | 0 | |||||
| >50 | 32 (18.8) | 206.5 (9.1) | 52.6 (9.3) | 101.4 (17.9) | 4.4 (0.31) | 5 (2.9) | |||||
| BMI (kg/m2) | |||||||||||
| ≤18.5: underweight | 8 (4.7) | 170.1 (13.6) | 0.297 | 42.6 (3.7) | 0.371 | 77.4 (15.3) | 0.117 | 4.0 (0.20) | 0.046c | 0 | 0.88 |
| 18.6–24.9: normal | 96 (56.5) | 173.8 (4.9) | 49.2 (1.6) | 99.0 (8.1) | 3.8 (0.13) | 3 (1.8) | |||||
| ≥25: overweight | 66 (38.8) | 193.7 (5.0) | 48.4 (1.8) | 104.1 (8.5) | 4.3 (0.17) | 2 (1.1) | |||||
| Nadir CD4 count (cells/mm3), Nd=83 | |||||||||||
| <350 | 73(87.9) | 177.7 (5.0) | 0.3016 | 49.4 (1.7) | 0.3517 | 102.7 (9.0) | 0.1214 | 3.8 (0.14) | 0.6789 | 0 | 0.71 |
| ≥350 | 10(12.1) | 192.3 (9.6) | 53.9 (4.0) | 63.9 (10.8) | 3.7 (0.23) | 4 (4.8) | |||||
| <500 | 79 (95.2) | ||||||||||
| ≥500 | 4 (4.8) | ||||||||||
| CD4-(cells/mm3), Nd=83 | |||||||||||
| <350 | 32 (38.6) | 177.9 (7.4) | 0.793 | 48.0 (3.0) | 0.3356 | 105.8 (13.7) | 0.4492 | 4.0 (0.21) | 0.3197 | 6 (3.7) | 0.73 |
| ≥350 | 51 (61.5) | 180.4 (5.9) | 51.2 (1.8) | 93.1 (10.1) | 3.7 (0.15) | 2 (1.2) | |||||
| <500 | 47 (56.6) | ||||||||||
| ≥500 | 36 (43.4) | ||||||||||
| ART use | |||||||||||
| ART− | 23 (13.5) | 147.8 (6.5) | 0.0001 | 39.2 (2.1) | 0.0013 | 95.8 (9.8) | 0.7716 | 3.99 (0.25) | 0.9616 | 1 (0.6) | 0.668 |
| ART+ | 147 (86.5) | 186.6 (3.8) | 50.0 (1.2) | 100.6 (6.4) | 4.01 (0.11) | 4 (2.3) | |||||
| MPO level (AAU/L) | |||||||||||
| <170 | 155 (91.2) | 182.2 (3.7) | 0.4789 | 49.0 (1.2) | 0.1767 | 83.0 (3.2) | >0.0001 | 4.0 (0.10) | 0.1149 | 5 (2.9) | 0.626 |
| ≥170 | 15 (8.8) | 173.3 (12.7) | 43.5 (4.9) | 275.8 (28.0) | 4.5 (0.45) | 0 | |||||
| hsCRP levels (mg/dL), N= 103 | |||||||||||
| >3 | 43 (41.8) | 168.6 (7.2) | 0.0502 | 47.2 (2.4) | 0.2447 | 78.8 (7.9) | 0.0758 | 3.8 (0.19) | 0.675 | 0 | 0.395 |
| <3 | 60 (58.2) | 186.2 (5.5) | 50.8 (2.0) | 103.6 (10.2) | 3.9 (0.15) | 1 (0.97) (Fisher’s) | |||||
Notes: AAU/L, units of measurement for MPO activity.
From one-way ANOVA using Bartlett’s tests for equal variances.
From chi-square using Fisher’s exact tests due to low numbers of patients. Data with >2 groups was tested by one-way ANOVA with Bonferroni adjustments for multiple testing.
Not significant after Bonferroni adjustment.
Only a sub-fraction of patients had this data. Italicized values represent significant P-values <0.05.
Abbreviations: ANOVA, analysis of variance; ART, antiretroviral therapy; BMI, body mass index; CD4, cluster of differentiation 4; HDL, high-density lipoprotein; hsCRP, highly sensitive C-reactive protein; LDL, low-density lipoprotein; MPO, myeloperoxidase; SE, standard error; TC, total cholesterol.